In the current scenario, therapeutics should be targeted for different putative genetic variants such as zeta-chain-associated protein kinase 70 (ZAP70), immunoglobulin lambda-like polypeptide 1 (iIGLL1), cluster of differentiation 79A (CD79A), collagen alpha-3 (VI) (COL6A3), COL3A1, COL1A1, CYP2C18, and CYP2C9, as potential therapeutic regimens for GC [28]. Here, COL6A3 is linked to gastric cancer.